Related Experiment Video
Updated: Mar 16, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.5K
Association between the X-ray repair cross-complementing group 1 Arg194Trp polymorphism and thyroid carcinoma
1Department of Head and Neck Surgery, Zhejiang Provincial Cancer Hospital, Hangzhou, China.
Genetics and Molecular Research : GMR
|August 16, 2016
Summary
The XRCC1 Arg194Trp polymorphism is linked to thyroid cancer risk in Caucasians. This genetic variation may increase susceptibility to thyroid cancer in this population.
Area of Science:
- Genetics
- Oncology
- Molecular Epidemiology
Background:
- Previous studies on the X-ray repair cross-complementing group 1 (XRCC1) Arg194Trp polymorphism and thyroid cancer (TC) risk have yielded conflicting results.
- Understanding genetic predispositions is crucial for identifying individuals at higher risk of developing thyroid cancer.
Purpose of the Study:
- To conduct a meta-analysis to clarify the association between the XRCC1 Arg194Trp polymorphism and thyroid cancer susceptibility.
- To consolidate evidence from existing case-control studies to provide a more definitive conclusion.
Main Methods:
- A comprehensive literature search was performed on PubMed and Web of Science databases up to August 2015.
- A meta-analysis was conducted using crude odds ratios (ORs) and 95% confidence intervals (CIs) to assess the risk associated with the XRCC1 Arg194Trp polymorphism.
- Data from five studies, including 911 thyroid cancer patients and 1476 controls, were analyzed.
Main Results:
- The meta-analysis revealed a significant association between the XRCC1 Arg194Trp polymorphism and thyroid cancer risk in Caucasian individuals.
- Specific models indicated elevated risk (e.g., TrpTrp vs ArgArg: OR = 5.72; ArgTrp vs ArgArg: OR = 1.20; dominant model: OR = 1.31).
- A protective effect was suggested under the recessive model (OR = 0.18).
Conclusions:
- The XRCC1 Arg194Trp polymorphism is identified as a risk factor for thyroid cancer in Caucasian populations.
- This finding contributes to understanding the genetic basis of thyroid cancer.
- Further research may explore the functional implications of this polymorphism in thyroid carcinogenesis.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
03:18Non-LTR Retrotransposons
13.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.9K
02:39lncRNA - Long Non-coding RNAs
10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K